The stock of Asterias Biotherapeutics Inc (NYSEMKT:AST) is a huge mover today! The stock increased 1.15% or $0.05 on November 15, hitting $4.4. About 192,309 shares traded hands or 44.05% up from the average. Asterias Biotherapeutics Inc (NYSEMKT:AST) has risen 1.15% since April 13, 2016 and is uptrending. It has underperformed by 2.78% the S&P500.
The move comes after 9 months negative chart setup for the $199.84M company. It was reported on Nov, 15 by Barchart.com. We have $3.83 PT which if reached, will make NYSEMKT:AST worth $25.98M less.
Asterias Biotherapeutics Inc (NYSEMKT:AST) Ratings Coverage
Out of 3 analysts covering Asterias Biotherapeutics (NYSEMKT:AST), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Asterias Biotherapeutics has been the topic of 4 analyst reports since August 11, 2015 according to StockzIntelligence Inc. On Thursday, September 3 the stock rating was upgraded by Zacks to “Hold”. As per Monday, May 23, the company rating was initiated by Chardan Capital Markets. As per Thursday, November 19, the company rating was initiated by FBR Capital. The company was maintained on Tuesday, August 11 by MLV.
According to Zacks Investment Research, “Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company’s technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California.”
More important recent Asterias Biotherapeutics Inc (NYSEMKT:AST) news were published by: Prnewswire.com which released: “Asterias Biotherapeutics Announces Record Date for Distribution of Warrants to …” on March 31, 2016, also Prnewswire.com published article titled: “Asterias Biotherapeutics Appoints Ryan Chavez as EVP of Finance and General …”, Prnewswire.com published: “Asterias Biotherapeutics Announces Positive Efficacy Data in Patients with …” on September 14, 2016. More interesting news about Asterias Biotherapeutics Inc (NYSEMKT:AST) was released by: Prnewswire.com and their article: “Asterias Biotherapeutics Announces Dosing of First Patient in New SCiSTAR …” with publication date: September 27, 2016.
AST Company Profile
Asterias Biotherapeutics, Inc., incorporated on October 24, 2012, is a biotechnology company. The Firm is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Firm has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. The Firm is focused on developing therapies to treat conditions with medical needs and inadequate available therapies, with an initial focus on the therapeutic areas of oncology and neurology. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient’s own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with its collaboration partner, Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells which could provide off the shelf cells that teaches a patient’s immune system to recognize and fight cancer cells, in non-small cell lung cancer. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells, in an initial clinical indication of spinal cord injury, with potential for later expansion into other neurodegenerative diseases, such as stroke and multiple sclerosis.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.